Adrian Rawcliffe Net Worth

The estimated Net Worth of Adrian Rawcliffe is at least $3.69 Milion dollars as of 16 January 2024. Mr. Rawcliffe owns over 39,384 units of Adaptimmune Therapeutics Plc stock worth over $48,436 and over the last 9 years he sold ADAP stock worth over $1,494,222. In addition, he makes $2,148,260 as Chief Executive Officer a Director at Adaptimmune Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rawcliffe ADAP stock SEC Form 4 insiders trading

Adrian has made over 22 trades of the Adaptimmune Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 39,384 units of ADAP stock worth $27,569 on 16 January 2024.

The largest trade he's ever made was selling 600,000 units of Adaptimmune Therapeutics Plc stock on 20 March 2018 worth over $1,026,000. On average, Adrian trades about 18,989 units every 51 days since 2016. As of 16 January 2024 he still owns at least 44,848 units of Adaptimmune Therapeutics Plc stock.

You can see the complete history of Mr. Rawcliffe stock trades at the bottom of the page.

Adrian Rawcliffe biography

Adrian Rawcliffe serves as Chief Executive Officer, Director of the Company. He leads our financial strategy, management and operations functions including compliance and risk management. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK's North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK's Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK's venture-capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.

What is the salary of Adrian Rawcliffe?

As the Chief Executive Officer a Director of Adaptimmune Therapeutics Plc, the total compensation of Adrian Rawcliffe at Adaptimmune Therapeutics Plc is $2,148,260. There are 1 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of $2,821,740.

How old is Adrian Rawcliffe?

Adrian Rawcliffe is 48, he's been the Chief Executive Officer a Director of Adaptimmune Therapeutics Plc since 2019. There are 18 older and 1 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.

What's Adrian Rawcliffe's mailing address?

Adrian's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.

Insiders trading at Adaptimmune Therapeutics Plc

Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.

What does Adaptimmune Therapeutics Plc do?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Complete history of Mr. Rawcliffe stock trades at Adaptimmune Therapeutics Plc a Wave Life Sciences

Adaptimmune Therapeutics Plc executives and stock owners

Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include:

• James Noble,
  Non-Executive Director
• Adrian Rawcliffe,
  Chief Executive Officer, Director
• William Bertrand,
  Chief Operating Officer
• Helen Tayton-Martin,
  Chief Business Officer
• Adrian G. Rawcliffe,
  CEO, Principal Accounting Officer & Director
• Dr. Helen Katrina Tayton-Martin MBA, Ph.D.,
  Co-Founder & Chief Bus. Officer
• William C. Bertrand Jr.,
  Chief Operating Officer
• Gavin Hilary James Wood BA (Hons), ACA,
  Chief Financial Officer
• David Mott,
  Non-Executive Independent Chairman of the Board
• Tal Zvi Zaks,
  Non-Executive Independent Director
• Elliott Sigal,
  Non-Executive Independent Director
• John Furey,
  Non-Executive Independent Director
• Barbara Duncan,
  Non-Executive Independent Director
• Ali Behbahani,
  Non-Executive Independent Director
• Lawrence Alleva,
  Non-Executive Independent Director
• John Lunger,
  Chief Patient Supply Officer
• Elliot Norry,
  Senior Vice President, Chief Medical Officer
• Gavin Wood,
  Chief Financial Officer
• Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Dr. Rafael G. Amado,
  Pres of R&D
• Sébastien Desprez,
  VP of Communications & Corp. Affairs
• Margaret Henry,
  Head of PR & Company Sec.
• Dr. Juli P. Miller Ph.D.,
  VP of Investor Relations
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Gwendolyn Knowlton Binder S...,
  EVP, Adaptimmune LLC
• Giles Francis Bertram Kerr,
  Director
• Jonathan Kenneth Charles Kn...,
  Director
• Forest Baskett,
  10% owner
• Ian Michael Laing,
  Director
• Rafael Amado,
  President, R&D
• Peter A. Thompson,
  Director
• Peter W. Sonsini,
  10% owner
• Patrick J Kerins,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 14, L...,
  
• Advisors Llc Orbi Med Capit...,
  
• Peter J Barris,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Kristen Hege,
  Director
• Priti Hegde,
  Director
• Andrew R Allen,
  Director
• Cintia Piccina,
  Chief Commercial Officer
• Joanna Elizabeth Brewer,
  Chief Scientific Officer
• Garry E Menzel,
  Director